Kiniksa Pharmaceuticals International (KNSA) Income from Continuing Operations (2017 - 2026)
Kiniksa Pharmaceuticals International (KNSA) posted Income from Continuing Operations of 22592000.0 for Q1 2026, down 25.53% on a QoQ basis from 30338000.0 in Q4 2025, and up 164.57% year-over-year from 8539000.0 in Q1 2025.
Kiniksa Pharmaceuticals International (KNSA) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International's Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 22592000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 164.57% year-over-year to 22592000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 89197000.0 (up 673.74% YoY) and the FY2025 annual result came in at 75144000.0, up 610.66% from the prior year.
- Income from Continuing Operations was 22592000.0 for Q1 2026 at Kiniksa Pharmaceuticals International, down from 30338000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 224093000.0 in Q3 2022 and bottomed at 276127000.0 in Q4 2022.
- A 5-year average of 6375823.53 and a median of 3908000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 833.67% in 2022, while the deepest fall reached 526.61% in 2022.
- Kiniksa Pharmaceuticals International's Income from Continuing Operations stood at 276127000.0 in 2022, then surged by 69.93% to 83032000.0 in 2023, then jumped by 123.59% to 19590000.0 in 2024, then jumped by 54.86% to 30338000.0 in 2025, then dropped by 25.53% to 22592000.0 in 2026.
- Business Quant data shows KNSA's Income from Continuing Operations at 22592000.0 in Q1 2026, 30338000.0 in Q4 2025, and 18435000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Kiniksa Pharmaceuticals International | 4.82 Bn | 4.36 Bn | 193.47 Mn | 22.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.59 Mn |
| Dec 31, 2025 | 30.34 Mn |
| Sep 30, 2025 | 18.44 Mn |
| Jun 30, 2025 | 17.83 Mn |
| Mar 31, 2025 | 8.54 Mn |
| Dec 31, 2024 | 19.59 Mn |
| Sep 30, 2024 | -12.69 Mn |
| Jun 30, 2024 | -3.91 Mn |
| Mar 31, 2024 | -17.70 Mn |
| Dec 31, 2023 | -83.03 Mn |
| Sep 30, 2023 | -13.86 Mn |
| Jun 30, 2023 | 14.97 Mn |
| Mar 31, 2023 | -12.27 Mn |
| Dec 31, 2022 | -276.13 Mn |
| Sep 30, 2022 | 224.09 Mn |
| Jun 30, 2022 | -19.98 Mn |
| Mar 31, 2022 | -25.21 Mn |
| Dec 31, 2021 | -44.07 Mn |
| Sep 30, 2021 | -30.54 Mn |
| Jun 30, 2021 | -41.56 Mn |